EyePoint (EYPT) Accounts Payables (2011 - 2026)
EyePoint (EYPT) posted Accounts Payables of $18.8 million for Q1 2026, up 79.34% sequentially from $10.5 million in Q4 2025, and up 14.58% YoY from $16.4 million in Q1 2025.
Analysis
EyePoint (EYPT) Accounts Payables (2011 - 2026) Analysis & Trends
EyePoint has reported Accounts Payables for 16 years, with the latest figure at $18.8 million in Q1 2026.
- Quarterly Accounts Payables rose 14.58% year-over-year to $18.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.8 million (up 14.58% YoY) and the FY2025 annual result came in at $10.5 million, down 10.5% from the prior year.
- Accounts Payables grew to $18.8 million in Q1 2026 per EYPT's latest filing, from $10.5 million in the prior quarter.
- Over five years, Accounts Payables peaked at $19.7 million in Q2 2025 and troughed at $5.9 million in Q4 2022.
- A 5-year average of $10.5 million and a median of $9.6 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables declined 25.08% in 2024, then surged 131.84% in 2025.
- Over 5 years, Accounts Payables stood at $5.9 million in 2022, then advanced by 9.88% to $6.5 million in 2023, then jumped by 80.21% to $11.7 million in 2024, then decreased by 10.5% to $10.5 million in 2025, then surged by 79.34% to $18.8 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $18.8 million, $10.5 million, and $10.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 17.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.27 Mn |
| Mar 31, 2026 | 18.81 Mn |
| Dec 31, 2025 | 10.49 Mn |
| Sep 30, 2025 | 10.08 Mn |
| Jun 30, 2025 | 19.69 Mn |
| Mar 31, 2025 | 16.42 Mn |
| Dec 31, 2024 | 11.72 Mn |
| Sep 30, 2024 | 7.34 Mn |
| Jun 30, 2024 | 14.30 Mn |
| Mar 31, 2024 | 7.08 Mn |
| Dec 31, 2023 | 6.50 Mn |
| Sep 30, 2023 | 9.58 Mn |
| Jun 30, 2023 | 10.72 Mn |
| Mar 31, 2023 | 9.45 Mn |
| Dec 31, 2022 | 5.92 Mn |
| Sep 30, 2022 | 6.11 Mn |
| Jun 30, 2022 | 7.06 Mn |
| Mar 31, 2022 | 7.30 Mn |
| Dec 31, 2021 | 7.39 Mn |
| Sep 30, 2021 | 6.64 Mn |